Recent Company News

• 04:23 PM ET Jan 22, 2026
  

  RedHill Biopharma guides Q4 revenue $6.5-$7.5M vs year-ago $8.0M in updated F-1 filing ($1.33, 0.00)

• 09:06 AM ET Jan 12, 2026
  

  Jaguar Health enters into U.S. license agreement with Future Pak for Crofelemer, providing up to $38M ($1.05, 0.00)

• 12:26 PM ET Jan 08, 2026
  

  RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

• 07:10 AM ET Jan 05, 2026
  

  RedHill Biopharma announces development progress for RHB-102 (Bekinda) ($1.03, 0.00)

• 07:12 AM ET Dec 15, 2025
  

  RedHill Biopharma announces Opaganib results indicating a reduction in Venetoclax resistant cells ($1.21, 0.00)

• 07:00 AM ET Dec 15, 2025
  

  RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

• 09:33 AM ET Nov 04, 2025
  

  RedHill Biopharma announces $10.5M NY supreme court judgment win against Kukbo ($1.54, +0.27)

• 09:04 AM ET Oct 20, 2025
  

  Cumberland (CPIX) to invest $4M for a 30% ownership stake in RedHill's global Talicia business. ($1.50, 0.00)

• 08:07 AM ET Oct 06, 2025
  

  RedHill Biopharma signs new $1.8M plus sales royalties Middle East deal for Talicia - 6-K ($1.90, 0.00)

• 07:05 AM ET Sep 29, 2025
  

  RedHill announces New York Supreme Court upholds company's $10M summary Judgment against Kukbo ($1.84, 0.00)